Welcome to our dedicated page for Mirati Therapeut news (Ticker: MRTX), a resource for investors and traders seeking the latest updates and insights on Mirati Therapeut stock.
Mirati Therapeutics, Inc. (NASDAQ: MRTX) is a commercial-stage biopharmaceutical company developing precision medicines for cancer treatment. This page provides investors and researchers with essential updates on clinical trial progress, regulatory milestones, and corporate developments shaping the future of oncology care.
Discover authoritative coverage of Mirati's innovative pipeline including KRAZATI® (adagrasib) for KRASG12C-mutated cancers and novel inhibitors targeting PRMT5 and KRASG12D. Our curated news feed delivers timely updates on FDA interactions, partnership announcements, and financial strategies critical for informed decision-making.
Key focus areas include treatment efficacy data, international regulatory approvals, and strategic leadership updates. Bookmark this page to stay informed about developments impacting MRTX's position in precision oncology and access to emerging therapies for high-need patient populations.
Mirati Therapeutics (NASDAQ: MRTX) will announce its third-quarter financial results and corporate updates on November 8, 2022, at 4:30 p.m. ET. A conference call will provide insights into the company's performance and updates. Investors can access the live webcast via Mirati's website or join by phone. Mirati is a clinical-stage biotechnology firm focused on advancing therapies for cancer patients, particularly in areas of high unmet medical need.
Mirati Therapeutics (MRTX) and Aadi Bioscience (AADI) announced a clinical collaboration on Oct. 12, 2022, to evaluate the combination of adagrasib, a KRASG12C inhibitor, and nab-sirolimus, an mTOR inhibitor, in patients with KRASG12C mutant non-small cell lung cancer (NSCLC). The Phase 1/2 trial aims to determine the optimal dosing, safety, and efficacy of the drug combination. Preclinical data showed enhanced anti-tumor efficacy when both agents were used together. The collaboration exemplifies their commitment to advancing targeted therapies for challenging cancers.
Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced the grant of equity awards to 22 new employees on October 3, 2022, as part of its Inducement Plan. These awards, crucial for employee acceptance, include options to purchase 70,610 shares at $68.36 each, and 44,119 restricted stock units (RSUs). The options will vest over four years, while the RSUs will vest gradually over four years as well. This move aligns with Nasdaq Listing Rule 5635(c)(4) and emphasizes Mirati's commitment to attracting talent as it advances its oncology-focused drug development pipeline.
Mirati Therapeutics (NASDAQ: MRTX) announced positive results from the Phase 1/2 KRYSTAL-1 study of adagrasib, a KRASG12C inhibitor, in advanced colorectal cancer (CRC). In 44 patients receiving adagrasib monotherapy, the objective response rate (ORR) was 19%, while the disease control rate (DCR) reached 86%. For 32 patients treated with the combination of adagrasib and cetuximab, the ORR was 46% and DCR was 100%. Both treatment strategies were well-tolerated, with mostly mild treatment-related adverse events.
Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced the granting of equity awards to 25 new employees as of September 1, 2022. These awards include options for 99,972 shares and 64,054 restricted stock units (RSUs). The options have an exercise price of $82.04 per share, aligning with the stock’s closing price on the grant date. The vesting schedule specifies that one-fourth of the options vest after one year, with the remainder vesting monthly over four years, dependent on continued employment.
Mirati Therapeutics, Inc. (NASDAQ: MRTX) will participate in two healthcare conferences on September 14, 2022. The first event is the Morgan Stanley Healthcare Conference at 8:35 a.m. ET, featuring CFO Laurie Stelzer and CCO Ben Hickey in a fireside chat. The second is the Bank of America Global Healthcare Conference at 2:10 p.m. BST, where CEO David Meek will represent the company. Interested parties can access a live webcast or replay on Mirati.com. The company is focused on delivering therapies for cancer treatment, particularly unmet needs in lung cancer.
Mirati Therapeutics (NASDAQ: MRTX) announced on August 4, 2022, the grant of equity awards to 56 new employees to enhance employment acceptance. A total of 177,751 stock options and 113,172 restricted stock units (RSUs) were granted, with options priced at $65.79, the stock's closing price on the grant date. Vesting for options occurs over four years, while RSUs vest 25% annually.
This initiative aims to incentivize employees and align their interests with shareholders as Mirati focuses on advancing its oncology pipeline.
Mirati Therapeutics (NASDAQ: MRTX) reported its second-quarter 2022 financial results, highlighting a significant net loss of $176.4 million or $3.18 per share. The company anticipates launching adagrasib for NSCLC patients with KRASG12C mutations in the U.S. and has submitted a Marketing Authorization Application in Europe. R&D expenses were $128.3 million, down from $134.6 million in Q2 2021, while G&A expenses rose to $54.2 million from $29.6 million. Mirati maintains a strong cash position of approximately $1.2 billion, supporting ongoing clinical programs.
Mirati Therapeutics (NASDAQ: MRTX) will announce its financial results for Q2 2022 and corporate updates on August 3, 2022, at 4:30 p.m. ET. A conference call will provide insights into the company's performance and future direction. Investors can tune in via webcast or through specified phone lines. Mirati is focused on developing innovative therapies for cancer, particularly targeting genetic drivers of the disease.
Mirati Therapeutics (MRTX) announced the first clinical data showing CNS activity of the KRASG12C inhibitor, adagrasib, in non-small cell lung cancer (NSCLC) patients with active untreated CNS metastases. In a Phase 1b KRYSTAL-1 study, approximately 32% of evaluable patients showed an intracranial (IC) response, with a disease control rate of 84%. The data was presented at the ASCO Annual Meeting on June 6, 2022. Mirati also planned a virtual investor event to discuss these findings and broader lung cancer strategies.
